| Literature DB >> 24456340 |
Chen-Shuan Chung, Li-Jen Liao, Wu-Chia Lo, Yueh-Hung Chou, Yi-Chen Chang, Yu-Chin Lin, Wei-Fan Hsu, Pei-Wei Shueng, Tzong-Hsi Lee.
Abstract
BACKGROUND: The prevalence of esophageal neoplasia in head and neck (H&N) cancer patients is not low; however, routine esophageal surveillance is not included in staging of newly-diagnosed H&N cancers. We aimed to investigate the risk factors for synchronous esophageal neoplasia and the impact of endoscopy on management of H&N cancer patients.Entities:
Mesh:
Year: 2013 PMID: 24456340 PMCID: PMC4028981 DOI: 10.1186/1471-230X-13-154
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Demographic characteristics and risk assessment of the study population
| 58.76 ± 9.20 | 55.63 ± 9.99 | 1.03 (0.99-1.08) | 0.130 | |
| <45 | 1 (3.3) | 12 (12.1) | referent | |
| 45~54 | 10 (33.3) | 40 (40.4) | 3.00 (0.34-26.82) | |
| ≧55 | 19 (63.3) | 47 (47.5) | 4.85 (0.56-41.94) | 0.077 |
| | | | | |
| Female | 2 (6.7) | 5 (5.1) | referent | |
| Male | 28 (93.3) | 94 (94.9) | 0.74 (0.14-4.05) | 0.733 |
| 21.64 ± 3.37 | 24.30 ± 4.85 | 0.86 (0.77-0.96)+ | 0.008 | |
| | | | | |
| Oral cavity | 8 (26.7) | 55 (55.6) | Referent | |
| Oropharynx | 6 (20) | 16 (16.2) | 1.50 (0.34-6.59) | 0.591 |
| Hypopharynx | 12 (40) | 20 (20.2) | 4.52 (1.46-13.99) | 0.009 |
| Larynx | 4 (13.3) | 4 (4.0) | 5.70 (1.08-29.99) | 0.040 |
| Nasopharynx | 0 | 4 (4.0) | NA | NA |
| | | | | |
| I | 4 (13.3) | 19 (19.2) | Referent | |
| II | 4 (13.3) | 14 (14.1) | ||
| III | 4 (13.3) | 12 (12.1) | 2.30 (0.98-5.42) | 0.056 |
| IV | 18 (60.0) | 51 (51.5) | ||
| | | | | |
| Non-drinker | 3 (10) | 32 (32.3) | Referent | |
| Drinker | 27 (90) | 67 (67.7) | 4.10 (1.16-14.56) | 0.029 |
| Light to moderate | 2 (6.7) | 10 (10.1) | 2.13 (0.30-15.12) | |
| Heavy | 25 (83.3) | 57 (57.6) | 4.68 (1.26-17.44) | 0.009 |
| | | | | |
| Non-chewer | 17 (56.7) | 33 (33.3) | Referent | |
| Chewer | 13 (43.3) | 66 (66.7) | 0.37 (0.16-0.84) | 0.018 |
| Light to moderate | 4 (13.3) | 31 (31.3) | 0.25 (0.07-0.87) | |
| Heavy | 9 (30.0) | 35 (35.4) | 0.50 (0.19-1.30) | 0.108 |
| | | | | |
| Non-smoker | 3 (10) | 18 (18.2) | Referent | |
| Smoker | 27 (90) | 81 (81.8) | 1.87 (0.51-6.86) | 0.348 |
| Light to moderate | 21 (70) | 60 (60.6) | 2.10 (0.55-7.97) | 0.528 |
| Heavy | 6 (20) | 21 (21.2) | 1.71 (0.37-8.05) | |
| | | | | |
| None | 1 | 7 | Referent | |
| 1 | 1 | 10 | 0.70 (0.03-14.35) | |
| 2 | 18 | 42 | 3.00 (0.33-27.09) | |
| 3 | 10 | 40 | 1.75 (0.19-16.29) | 0.680 |
Abbreviation: BMI body mass index, H&N head and neck, NA not applicable, OR odds ratio, CI confidence interval.
*Including low-grade, high-grade intraepithelial neoplasia and invasive carcinoma; + Risk assessment every 1-kg/m2 increment.
Note that the lifestyle risk factors were recorded according to the frequencies (alcohol on a weekly basis where one time indicates at least 15.75 gm of ethanol: 0, never; 1, once; 2, once to twice; 3, 3–4 times; and 4, ≥5 times; betel quid on a piece per day basis: 0, never; 1, <1 piece; 2, 1–10 pieces; 3, 11–20 pieces; and 4, >20 pieces; cigarettes on a pack per day basis: 0, never; 1, <0.5 pack; 2, 0.5–1 pack; 3, 1–2 packs; and 4, >2 packs) and duration (0, never; 1, <1 year; 2, 1–10 years; 3, 11–20 years; and 4, >20 years). The cumulative lifetime exposure was calculated by multiplying the frequency and duration, and further categorized into these three levels: level 1, never (0); level 2, light to moderate (1–11); and level 3, heavy (≥12).
Figure 1Endoscopic surveillance and management of synchronous high-grade intraepithelial neoplasia of esophagus in a laryngeal cancer patient. A, A flat superficial neoplasia with hyperemia in white-light imaging system. B, A superficial neoplasia with brownish discoloration under narrow-band imaging system. C, Lugol-voiding of the neoplasia after spraying a 1.5% Lugol’s solution. D, Abnormal intraepithelial capillary loops under narrow-band imaging system with magnifying endoscopy. E, Endoscopic submucosal dissection of the superficial neoplasia. F, Mucosal cancer invading the lamina propria (main picture: HE stain, 40x; right bottom: HE stain, 100x).
Multivariate logistic regression model for risk assessment
| 1.62 (0.59-4.44) | 0.350 | |
| 0.17 (0.01-2.00) | 0.161 | |
| 0.87 (0.76-0.99) | 0.036 | |
| 2.98 (1.11-7.99) | 0.030 | |
| 5.90 (1.23-26.44) | 0.020 | |
| 0.59 (0.21-1.65) | 0.318 | |
| 1.39 (0.29-6.60) | 0.679 | |
| 1.52 (0.54-4.27) | 0.423 | |
| 4.41 (0.80-24.24) | 0.088 |
Abbreviation: H&N head and neck, OR odds ratio, CI confidence interval.
*Risk assessment for esophageal low-grade, high-grade intraepithelial neoplasia, and invasive carcinoma.
Characteristics of esophageal lesions and diagnostic performance of endoscopy
| | ||
| Total biopsied lesions | 60 (100.0) | |
| Chronic inflammation | 3 (5.0) | |
| Squamous hyperplasia | 17 (28.3) | |
| LGIN | 11 (18.3) | |
| HGIN | 14 (23.3) | |
| Invasive carcinoma | 12 (20.0) | |
| Others | 3 (5.0) | |
| 60/37 (100) | - | |
| WLI | 24/19 (51.4) | 51.4 / 78.3 / 61.7 |
| NBI-ME | 37/36 (97.3) | 97.3 / 94.1 / 96.3 |
| LC | 48/36 (97.3) | 97.3 / 52.2 / 81.7 |
| | ||
| Upper third | 9 (15.0) | |
| Middle third | 26 (43.3) | |
| Lower third | 25 (41.7) | |
| | ||
| Single | 46 (86.8) | |
| Multifocal | 7 (13.2) | |
Abbreviation: WLI white-light imaging, NBI-ME narrow-band imaging system with magnifying endoscopy, LC Lugol’s chromoendoscopy, LGIN low-grade intraepithelial neoplasia, HGIN high-grade intraepithelial neoplasia.
*Detection of low-grade, high-grade intraepithelial neoplasia and invasive carcinoma by histological confirmation.
Tumor board review of H&N cancer patients with modified treatment strategy after IEE screening
| 1 | Oropharynx / II | Lower third / 0.3 / LGIN | Tumor excision | Tumor excision + EMR of esophageal lesion |
| 2 | Hypopharynx / I | Middle third / 0.5 / LGIN | Tumor excision | Tumor excision + EMR of esophageal lesion |
| 3 | Oropharynx / III | Lower third / 0.5 / LGIN | Tumor excision + LN dissection + Adjuvant CCRT | Tumor excision + EMR of esophageal lesion + Adjuvant CCRT |
| 4 | Hypopharynx / III | Middle third / 6.0 / SCC (IIA) | Tumor excision + LN dissection + Adjuvant CCRT | Tumor excision + Adjuvant CCRT with RT field involving esophagus |
| 5 | Larynx / I | Middle / 1.5 / HGIN | Laryngectomy | Laryngectomy + ESD of esophageal lesion |
| 6 | Larynx / I | Upper / 6.0 / SCC (IB) | Laryngectomy | Laryngectomy + Esophagectomy + Adjuvant CCRT |
| 7 | Oropharynx / IVA | Upper / 0.6 / SCC (IA) | Neoadjuvant CCRT + Tumor excision + LN dissection | Neoadjuvant CCRT + Tumor excision + Esophagectomy |
| 8 | Oropharynx / II | Middle / 4.0 / SCC (IA) | Tumor excision + Adjuvant CCRT | Tumor excision + Esophagectomy + Adjuvant CCRT |
| 9 | Hypopharynx/IVA | Middle / 2.0 / HGIN | Tumor excision + LN dissection + Adjuvant CCRT | Tumor excision + LN dissection + RFA of esophageal lesion + Adjuvant CCRT |
| 10 | Hypopharynx / IVB | Upper / 1.5 / SCC(IB) | Definitive CCRT | Definitive CCRT with RT field involving the esophagus |
| 11 | Hypopharynx/III | Middle / 5.0 / SCC (IIIA) | Tumor excision + LN dissection + Adjuvant CCRT | Neoadjuvant CCRT + Tumor excision + LN dissection + Esophagectomy |
| 12 | Hypopharynx / IVB | Middle / 1.5 / SCC (IIIA) | Definitive CCRT | Definitive CCRT with RT filed involving the esophagus |
| 13 | Oral cavity / II | Lower / 0.2 / LGIN | Tumor excision | Tumor excision + EMR of esophageal lesion |
| 14 | Hypopharynx / III | Middle / 0.8 / HGIN | Tumor excision + LN dissection + Adjuvant CCRT | Tumor excision + LN dissection + ESD of esophageal lesion + Adjuvant CCRT |
| 15 | Oral cavity / I | Upper / 2.0 / SCC ( IB) | Tumor excision | Tumor excision + Esophagectomy |
| 16 | Oral cavity / II | Middle / 1.0 / SCC (IA) | Tumor excision | Tumor excision + EMR of esophageal lesion |
| 17 | Oral cavity / IVB | Middle / 2.0 / SCC (IIIA) | Definitive CCRT | Definitive CCRT with RT field involving esophagus |
| 18 | Hypopharynx / IVA | Upper / 2.0 / SCC (IB) | Tumor excision + LN dissection + Adjuvant CCRT | Tumor excision + LN dissection + Adjuvant CCRT with RT field involving esophagus |
| 19 | Hypopharynx / IVA | Middle / 0.8 / HGIN | Tumor excision + LN dissection + Adjuvant CCRT | Tumor excision + LN dissection + EMR + Adjuvant CCRT |
| 20 | Larynx / IVA | Middle / 6.0 / SCC (IB) | Laryngectomy + Adjuvant CCRT | Laryngectomy + Esophagectomy + Adjuvant CCRT |
Abbreviation: CCRT concurrent chemoradiotherapy, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, H&N head and neck, HGIN high-grade intraepithelial neoplasia, IEE image-enhanced endoscopy, LN lymph node, LGIN low-grade intraepithelial neoplasia, RFA radiofrequency ablation, SCC squamous cell carcinoma.